Axion BioSystems creates tools for understanding human heart and brain activity. The company’s novel platform is a proprietary microelectronic system that enables precise manipulation of human cells and tissue.
Axion’s flagship product, the Maestro, is the first commercially available multiple micro electrode array (MEA). This in vitro tool, which models brain activity in a dish, is used to evaluate drug toxicity, develop lead compounds and create phenotypic models.
Axion’s tools offer a range of biomedical applications — life science instrumentation, medical diagnostics and implantable devices — with relevance to the pharmaceutical and biotech industries and academic and government research.
Company website: Axion Biosystems
Back to companies
Axion’s flagship product, the Maestro, is the first commercially available multiple micro electrode array (MEA). This in vitro tool, which models brain activity in a dish, is used to evaluate drug toxicity, develop lead compounds and create phenotypic models.
Axion’s tools offer a range of biomedical applications — life science instrumentation, medical diagnostics and implantable devices — with relevance to the pharmaceutical and biotech industries and academic and government research.
Company website: Axion Biosystems
Back to companies
Location: United States, Georgia, Atlanta
Total raised: $8M
Investors 3
| Date | Name | Website |
| - | Georgia Re... | gra.org |
| - | GRA Ventur... | graventure... |
| - | Summa Equi... | summaequit... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 26.09.2018 | - | $8M | - |
Mentions in press and media 6
| Date | Title | Description |
| 15.09.2026 | The Scientist Announces the 2026 Top Innovations Winners | Ten groundbreaking technologies are recognized across biotechnology, healthcare, lab tools, and startup innovations. WILMINGTON, Del., Sept. 15, 2026 /PRNewswire-PRWeb/ -- The Scientist proudly unveils the winners of this year's Top Innovat... |
| 31.01.2023 | Axion BioSystems Launches New High-Throughput Live-Cell Imaging Platform, Omni Pro 12 | Axion BioSystems announces the addition of the Omni Pro 12 to the Omni live-cell imaging product family. The new platform, which features integrated robotics and a multiplate design compatible with any standard incubator, offers enhanced fl... |
| 16.07.2021 | Summa Equity acquires Axion BioSystems, to accelerate understanding of cell behaviour in drug discovery and development | Summa Equity acquires Axion BioSystems, to accelerate understanding of cell behaviour in drug discovery and development Fri, Jul 16, 2021 14:00 CET Summa Equity Fund II has acquired Axion BioSystems, a US life science tools business special... |
| 16.07.2021 | The continued divvying up of the Weinstein Company | This is the web version of Term Sheet, a daily newsletter on the biggest deals and dealmakers. Sign up to get it delivered free to your inbofx. Paid Content 5 ways to build trust at your company—and why it matters From PwC The film shop tha... |
| 16.07.2021 | The continued divvying up of the Weinstein Company | This is the web version of Term Sheet, a daily newsletter on the biggest deals and dealmakers. Sign up to get it delivered free to your inbofx. Paid Content How one health care company stays true to its mission From Viatris The film shop th... |
| 15.07.2021 | Summa Equity acquires Axion BioSystems, to accelerate understanding of cell behaviour in drug discovery and development | Summa Equity Fund II has acquired Axion BioSystems, a US life science tools business specializing in the development, production, and marketing of MEA (Microelectrode Arrays) and impedance technologies. Its tools are used to understand cell... |